2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide (BioDeep_00000842232)

   


代谢物信息卡片


2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide

化学式: C13H16N4O (244.13240459999997)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N
InChI: InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)

描述信息

D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors
D004791 - Enzyme Inhibitors

同义名列表

1 个代谢物同义名

2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Peirong Wang, Ruizhen Zhao, Xiaohui Jin, Xianhua Zhou, Xiaolong Xie. Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis. Cancer investigation. 2024 Mar; 42(3):260-273. doi: 10.1080/07357907.2024.2338128. [PMID: 38588003]
  • Shannon L Puhalla, Véronique Diéras, Banu K Arun, Bella Kaufman, Hans Wildiers, Hyo S Han, Jean-Pierre Ayoub, Vered Stearns, Yuan Yuan, Teresa Helsten, Bridget Riley-Gillis, Erin Murphy, Madan G Kundu, Meijing Wu, David Maag, Christine K Ratajczak, Cyril Y Ramathal, Michael Friedlander. Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 09; 27(18):4983-4993. doi: 10.1158/1078-0432.ccr-21-0748. [PMID: 34131001]
  • Sven Stodtmann, Silpa Nuthalapati, Doerthe Eckert, Sreeneeranj Kasichayanula, Rujuta Joshi, Bruce A Bach, Sven Mensing, Rajeev Menon, Hao Xiong. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. Journal of clinical pharmacology. 2021 09; 61(9):1195-1205. doi: 10.1002/jcph.1875. [PMID: 33894017]
  • S Vajapeyam, D Brown, C Billups, Z Patay, G Vezina, M S Shiroishi, M Law, P Baxter, A Onar-Thomas, J R Fangusaro, I J Dunkel, T Y Poussaint. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. AJNR. American journal of neuroradiology. 2020 04; 41(4):718-724. doi: 10.3174/ajnr.a6499. [PMID: 32241771]
  • M A C Bruin, N de Vries, L Lucas, H Rosing, A D R Huitema, J H Beijnen. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Feb; 1138(?):121925. doi: 10.1016/j.jchromb.2019.121925. [PMID: 31915109]
  • Y F Li, L M Wen, J Zhao, G D Lv, S Lu, S Lu, X Zheng, B Chen, C Y Tian, Y H Gong, H J Gao, J H Wang. In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus. Disease markers. 2020; 2020(?):8259820. doi: 10.1155/2020/8259820. [PMID: 32714467]
  • Taofeek K Owonikoko, Suzanne E Dahlberg, Gabriel L Sica, Lynne I Wagner, James L Wade, Gordan Srkalovic, Bradley W Lash, Joseph W Leach, Ticiana B Leal, Charu Aggarwal, Suresh S Ramalingam. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 01; 37(3):222-229. doi: 10.1200/jco.18.00264. [PMID: 30523756]
  • Xun Bao, Jianmei Wu, Seongho Kim, Patricia LoRusso, Jing Li. Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients. Journal of clinical pharmacology. 2019 01; 59(1):20-34. doi: 10.1002/jcph.1275. [PMID: 30052267]
  • Heidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, Mihaela Cristea, Hao Xiong, Danielle Sullivan, Yan Luo, Mark D McKee, Wijith Munasinghe, Lainie P Martin. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic oncology. 2018 03; 148(3):507-514. doi: 10.1016/j.ygyno.2017.12.029. [PMID: 29352572]
  • Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, Harry J Long, Donald W Northfelt, Joel M Reid, Felix Boakye-Agyeman, Olumide Kayode, Karen S Flatten, Maria I Harrell, Elizabeth M Swisher, Guy G Poirier, Daniel Satele, Jake Allred, Janet L Lensing, Alice Chen, Jiuping Ji, Yiping Zang, Charles Erlichman, Paul Haluska, Scott H Kaufmann. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 02; 24(4):744-752. doi: 10.1158/1078-0432.ccr-17-1590. [PMID: 29138343]
  • Silpa Nuthalapati, Wijith Munasinghe, Vincent Giranda, Hao Xiong. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clinical pharmacokinetics. 2018 01; 57(1):51-58. doi: 10.1007/s40262-017-0547-z. [PMID: 28497258]
  • Imke H Bartelink, Brendan Prideaux, Gregor Krings, Lisa Wilmes, Pei Rong Evelyn Lee, Pan Bo, Byron Hann, Jean-Philippe Coppé, Diane Heditsian, Lamorna Swigart-Brown, Ella F Jones, Sergey Magnitsky, Ron J Keizer, Niels de Vries, Hilde Rosing, Nela Pawlowska, Scott Thomas, Mallika Dhawan, Rahul Aggarwal, Pamela N Munster, Laura J Esserman, Weiming Ruan, Alan H B Wu, Douglas Yee, Véronique Dartois, Radojka M Savic, Denise M Wolf, Laura van 't Veer. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast cancer research : BCR. 2017 Sep; 19(1):107. doi: 10.1186/s13058-017-0896-4. [PMID: 28893315]
  • Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jacqueline M Greer, Richard Piekarz, Judith E Karp, Keith Pratz, Michelle A Rudek. Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. British journal of clinical pharmacology. 2017 08; 83(8):1688-1700. doi: 10.1111/bcp.13253. [PMID: 28156017]
  • Jing Niu, Christie Scheuerell, Shailly Mehrotra, Sharon Karan, Shannon Puhalla, Brian F Kiesel, Jiuping Ji, Edward Chu, Mathangi Gopalakrishnan, Vijay Ivaturi, Jogarao Gobburu, Jan H Beumer. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types. Journal of clinical pharmacology. 2017 08; 57(8):977-987. doi: 10.1002/jcph.892. [PMID: 28387939]
  • Martin Reck, Normand Blais, Erzsebet Juhasz, Vera Gorbunova, C Michael Jones, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Keilholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dziubinski, Hao Xiong, Rajendar K Mittapalli, Martin Dunbar, Peter Ansell, Lei He, Mark McKee, Vincent Giranda, Suresh S Ramalingam. Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 07; 12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. [PMID: 28461256]
  • Rajendar K Mittapalli, Silpa Nuthalapati, Alyssa E Delke DeBord, Hao Xiong. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation. Pharmaceutical research. 2017 06; 34(6):1187-1192. doi: 10.1007/s11095-017-2133-3. [PMID: 28243955]
  • Michal Yalon, Liron Tuval-Kochen, David Castel, Itai Moshe, Inbal Mazal, Osher Cohen, Camila Avivi, Kineret Rosenblatt, Sarit Aviel-Ronen, Ginette Schiby, Joachim Yahalom, Ninette Amariglio, Raphael Pfeffer, Yaacov Lawrence, Amos Toren, Gideon Rechavi, Shoshana Paglin. Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PloS one. 2016; 11(5):e0155711. doi: 10.1371/journal.pone.0155711. [PMID: 27196668]
  • Rutger K Balvers, Martine L M Lamfers, Jenneke J Kloezeman, Anne Kleijn, Lotte M E Berghauser Pont, Clemens M F Dirven, Sieger Leenstra. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. Journal of translational medicine. 2015 Feb; 13(?):74. doi: 10.1186/s12967-015-0427-y. [PMID: 25886061]
  • Jack M Su, Patrick Thompson, Adekunle Adesina, Xiao-Nan Li, Lindsay Kilburn, Arzu Onar-Thomas, Mehmet Kocak, Brenda Chyla, Evelyn McKeegan, Katherine E Warren, Stewart Goldman, Ian F Pollack, Maryam Fouladi, Alice Chen, Vincent Giranda, James Boyett, Larry Kun, Susan M Blaney. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro-oncology. 2014 Dec; 16(12):1661-8. doi: 10.1093/neuonc/nou103. [PMID: 24908656]
  • Jing Li, Seongho Kim, Xianyi Sha, Richard Wiegand, Jianmei Wu, Patricia LoRusso. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Aug; 20(15):3931-44. doi: 10.1158/1078-0432.ccr-14-0791. [PMID: 24947923]
  • Fan Lin, Mark C de Gooijer, Eloy Moreno Roig, Levi C M Buil, Susan M Christner, Jan H Beumer, Thomas Würdinger, Jos H Beijnen, Olaf van Tellingen. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 May; 20(10):2703-13. doi: 10.1158/1078-0432.ccr-14-0084. [PMID: 24647572]
  • Ryota Kikuchi, Yanbin Lao, Daniel A J Bow, William J Chiou, Mark E Andracki, Robert A Carr, Richard L Voorman, Sonia M De Morais. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). Journal of pharmaceutical sciences. 2013 Dec; 102(12):4426-32. doi: 10.1002/jps.23737. [PMID: 24122511]
  • Carey K Anders, Barbara Adamo, Olga Karginova, Allison M Deal, Sumit Rawal, David Darr, Allison Schorzman, Charlene Santos, Ryan Bash, Tal Kafri, Lisa Carey, C Ryan Miller, Charles M Perou, Norman Sharpless, William C Zamboni. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PloS one. 2013; 8(5):e61359. doi: 10.1371/journal.pone.0061359. [PMID: 23650496]
  • Shivaani Kummar, Alice Chen, Jiuping Ji, Yiping Zhang, Joel M Reid, Matthew Ames, Lee Jia, Marcie Weil, Giovanna Speranza, Anthony J Murgo, Robert Kinders, Lihua Wang, Ralph E Parchment, John Carter, Howard Stotler, Larry Rubinstein, Melinda Hollingshead, Giovanni Melillo, Yves Pommier, William Bonner, Joseph E Tomaszewski, James H Doroshow. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer research. 2011 Sep; 71(17):5626-34. doi: 10.1158/0008-5472.can-11-1227. [PMID: 21795476]
  • Xiaofeng Li, Juergen Delzer, Richard Voorman, Sonia M de Morais, Yanbin Lao. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug metabolism and disposition: the biological fate of chemicals. 2011 Jul; 39(7):1161-9. doi: 10.1124/dmd.110.037820. [PMID: 21436403]
  • Sarah Reinhardt, Ming Zhao, Aleksander Mnatsakanyan, Linping Xu, Rebecca M Ricklis, Alice Chen, Judith E Karp, Michelle A Rudek. A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. Journal of pharmaceutical and biomedical analysis. 2010 May; 52(1):122-8. doi: 10.1016/j.jpba.2009.12.015. [PMID: 20071126]
  • Jodi A Muscal, Patrick A Thompson, Vincent L Giranda, Brian D Dayton, Joy Bauch, Terzah Horton, Leticia McGuffey, Jed G Nuchtern, Robert C Dauser, Brian W Gibson, Susan M Blaney, Jack M Su. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer chemotherapy and pharmacology. 2010 Feb; 65(3):419-25. doi: 10.1007/s00280-009-1044-3. [PMID: 19526240]
  • Richard Wiegand, Jianmei Wu, Xianyi Sha, Patricia LoRusso, Jing Li. Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Feb; 878(3-4):333-9. doi: 10.1016/j.jchromb.2009.11.037. [PMID: 20005184]
  • Robert A Parise, Mohammad Shawaqfeh, Merrill J Egorin, Jan H Beumer. Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Sep; 872(1-2):141-7. doi: 10.1016/j.jchromb.2008.07.032. [PMID: 18692448]
  • Joann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, Jennifer J Bouska, Gail Bukofzer, Milagros Colon-Lopez, Ran Guan, Kenneth Jarvis, Eric F Johnson, Vered Klinghofer, Xuesong Liu, Amanda Olson, Mary J Saltarelli, Yan Shi, Jason A Stavropoulos, Gui-Dong Zhu, Thomas D Penning, Yan Luo, Vincent L Giranda, Saul H Rosenberg, David J Frost, Cherrie K Donawho. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer research. 2008 Sep; 28(5A):2625-35. doi: NULL. [PMID: 19035287]